Nuclear Medicine Communications

Home Current Issue Previous Issues Published Ahead-of-Print For Authors Journal Info
Skip Navigation LinksHome > June 2008 - Volume 29 - Issue 6 > Role of serial quantitative gallium-67 tumor uptake in asses...
Nuclear Medicine Communications:
June 2008 - Volume 29 - Issue 6 - pp 527-534
doi: 10.1097/MNM.0b013e3282f81366
Original Articles

Role of serial quantitative gallium-67 tumor uptake in assessing response rates for chemotherapy in lymphoma patients

Ballani, Nasser S.; Khan, Haider A.; Al-Mohannadi, Shihab H.; Al-Huda, Fawaz Abu; Usmani, Sharjeel; Tuli, Mahmoud M.; Al-Shemmari, Salem H.; Al-Sawagh, Hanan F.; Al-Enezi, Farha H.

Collapse Box

Abstract

Purpose: To evaluate in serial gallium-67 scans (GS) the role of semiquantitative tumor-to-background (Tm/Bg) and tumor-to-liver ratios in assessing response rates to chemotherapy, in Hodgkin's disease and non-Hodgkin's lymphoma.

Materials and methods: Twenty-seven consecutive patients (15 Hodgkin's disease and 12 non-Hodgkin's lymphoma patients) with an average age of 30 (range, 5-60) years underwent GS at prechemotherapy, early chemotherapy (after first cycle), and postchemotherapy. Average tumor, background, and liver region of interest counts obtained and Tm/Bg, tumor-to-liver, and liver region to background ratios were derived for each patient on serial GS. All patients were assessed by visual and quantitative GS and followed up clinically for more than 7 years.

Results: At early visual GS, 70% (19 of 27) of the patients showed rapid response, 15% (four of 27) showed delayed response (negative at post-GS), and 15% showed no response. Mean early-GS Tm/Bg ratio of disease-free patients (1±0.04) was significantly different from relapsed (1.4±0.2) (P<0.025) and progressive disease (1.8±0.7) patients. A significant difference was noted (P<0.01) in serial paired comparisons of Tm/Bg ratios between pretherapy and early-therapy scans in relapsed patients, whereas progressive disease patients showed no significant change during the same time. At early-GS, 15 patients showed quantitative rapid response (Tm/Bg ratio 1.04), nine patients showed quantitative delayed response (Tm/Bg ratio >1.04 with significant serial change between pretherapy and early-therapy GS), and three patients showed quantitative no response (Tm/Bg ratio >1.04 with nonsignificant serial change between pretherapy and posttherapy GS).

Conclusion: Quantitative GS is an effective tool in the detection of early response to chemotherapy. Quantitative response rates after the first cycle can more reliably identify patients who are most likely to be disease-free or relapse after first-line therapy or those that will show no response to therapy as compared with visual analysis alone.

© 2008 Lippincott Williams & Wilkins, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Article Tools

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.